Induction of antibodies directed against self and altered-self determinants by a synthetic adjuvant, muramyl dipeptide and some of its derivatives.
In a serum free, 2-mercaptoethanol supplemented culture medium muramyl dipeptide (MDP) is able to increase the number of plaque-forming cells (PFC) directed against syngeneic, bromelain-treated red blood cells (br-MRBC) and against an autoantigen, mouse albumin. The non-specific stimulation of anti-br-MRBC PFC by MDP, as by bacterial lipopolysaccharide (LPS), can be observed in spleen cell populations depleted of adherent and phagocytic cells, and in nu/nu spleen cell cultures. However, the kinetics of the induction of anti-br-MRBC PFC in murine spleen cell cultures in presence of LPS or of MDP are not identical. Moreover, MDP is able to stimulate C3H/He Orl (LPS low-responder strain) cells. Thus, the mechanisms of non-specific stimulation by MDP or by LPS could be different. Experiments done with thirteen structural analogues of MDP showed that there exists a good correlation between the adjuvant activity and the ability to induce anti-br-MRBC PFC.
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000276:immunology*; D000276:Adjuvants, Immunologic; D000818:Animals; D001323:Autoantibodies / Q000096:biosynthesis*; D002478:Cells, Cultured; D000939:Epitopes; D006020:Glycopeptides / Q000276:immunology*; D006462:Hemolytic Plaque Technique; D007518:Isoantibodies / Q000096:biosynthesis; D007700:Kinetics; D008070:Lipopolysaccharides / Q000276:immunology; D051379:Mice; D008819:Mice, Nude; D013154:Spleen / Q000166:cytology / Q000276:immunology
D000276:Adjuvants, Immunologic; D001323:Autoantibodies; D000939:Epitopes; D006020:Glycopeptides; D007518:Isoantibodies; D008070:Lipopolysaccharides; D000119:Acetylmuramyl-Alanyl-Isoglutamine